Macrophage interleukin-6 and tumour necrosis factor-alpha are induced by coronavirus fixation to Toll-like receptor 2/heparan sulphate receptors but not carcinoembryonic cell adhesion antigen 1a.
Identifieur interne : 001823 ( PubMed/Corpus ); précédent : 001822; suivant : 001824Macrophage interleukin-6 and tumour necrosis factor-alpha are induced by coronavirus fixation to Toll-like receptor 2/heparan sulphate receptors but not carcinoembryonic cell adhesion antigen 1a.
Auteurs : Alexandre Jacques ; Christian Bleau ; Claire Turbide ; Nicole Beauchemin ; Lucie LamontagneSource :
- Immunology [ 1365-2567 ] ; 2009.
English descriptors
- KwdEn :
- Animals, Butadienes (pharmacology), Carcinoembryonic Antigen (genetics), Carcinoembryonic Antigen (metabolism), Cell Line, Coronavirus Infections (complications), Enzyme Inhibitors (pharmacology), Fibroblasts (drug effects), Fibroblasts (metabolism), Fibroblasts (virology), Heparitin Sulfate (immunology), Heparitin Sulfate (metabolism), Hepatitis, Animal (immunology), Hepatitis, Animal (virology), Imidazoles (pharmacology), Interleukin-6 (agonists), Interleukin-6 (biosynthesis), Liver (immunology), Liver (pathology), Liver (virology), Macrophages, Peritoneal (drug effects), Macrophages, Peritoneal (immunology), Macrophages, Peritoneal (virology), Membrane Glycoproteins (immunology), Mice, Mice, Knockout, Murine hepatitis virus (immunology), Nitriles (pharmacology), Protein-Serine-Threonine Kinases (antagonists & inhibitors), Protein-Serine-Threonine Kinases (immunology), Protein-Serine-Threonine Kinases (metabolism), Pyridines (pharmacology), Spike Glycoprotein, Coronavirus, Toll-Like Receptor 2 (genetics), Toll-Like Receptor 2 (metabolism), Tumor Necrosis Factor-alpha (agonists), Tumor Necrosis Factor-alpha (metabolism), Viral Envelope Proteins (immunology), Virus Replication (immunology), p38 Mitogen-Activated Protein Kinases (antagonists & inhibitors), p38 Mitogen-Activated Protein Kinases (immunology), p38 Mitogen-Activated Protein Kinases (metabolism).
- MESH :
- chemical , agonists : Interleukin-6, Tumor Necrosis Factor-alpha.
- chemical , antagonists & inhibitors : Protein-Serine-Threonine Kinases, p38 Mitogen-Activated Protein Kinases.
- chemical , biosynthesis : Interleukin-6.
- chemical , genetics : Carcinoembryonic Antigen, Toll-Like Receptor 2.
- chemical , immunology : Heparitin Sulfate, Membrane Glycoproteins, Protein-Serine-Threonine Kinases, Viral Envelope Proteins, p38 Mitogen-Activated Protein Kinases.
- chemical , metabolism : Carcinoembryonic Antigen, Heparitin Sulfate, Protein-Serine-Threonine Kinases, Toll-Like Receptor 2, Tumor Necrosis Factor-alpha, p38 Mitogen-Activated Protein Kinases.
- chemical , pharmacology : Butadienes, Enzyme Inhibitors, Imidazoles, Nitriles, Pyridines.
- complications : Coronavirus Infections.
- drug effects : Fibroblasts, Macrophages, Peritoneal.
- immunology : Hepatitis, Animal, Liver, Macrophages, Peritoneal, Murine hepatitis virus, Virus Replication.
- metabolism : Fibroblasts.
- pathology : Liver.
- virology : Fibroblasts, Hepatitis, Animal, Liver, Macrophages, Peritoneal.
- Animals, Cell Line, Mice, Mice, Knockout, Spike Glycoprotein, Coronavirus.
Abstract
A rapid antiviral immune response may be related to viral interaction with the host cell leading to activation of macrophages via pattern recognition receptors (PPRs) or specific viral receptors. Carcinoembryonic cell adhesion antigen 1a (CEACAM1a) is the specific receptor for the mouse hepatitis virus (MHV), a coronavirus known to induce acute viral hepatitis in mice. The objective of this study was to understand the mechanisms responsible for the secretion of high-pathogenic MHV3-induced inflammatory cytokines. We report that the induction of the pro-inflammatory cytokines interleukin (IL)-6 and tumour necrosis factor (TNF)-alpha in peritoneal macrophages does not depend on CEACAM1a, as demonstrated in cells isolated from Ceacam1a(-/-) mice. The induction of IL-6 and TNF-alpha production was related rather to the fixation of the spike (S) protein of MHV3 on Toll-like receptor 2 (TLR2) in regions enriched in heparan sulphate and did not rely on viral replication, as demonstrated with denatured S protein and UV-inactivated virus. High levels of IL-6 and TNF-alpha were produced in livers from infected C57BL/6 mice but not in livers from Tlr2(-/-) mice. The histopathological observations were correlated with the levels of those inflammatory cytokines. Depending on mouse strain, the viral fixation to heparan sulfate/TLR2 stimulated differently the p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-kappaB in the induction of IL-6 and TNF-alpha. These results suggest that TLR2 and heparan sulphate receptors can act as new viral PPRs involved in inflammatory responses.
DOI: 10.1111/j.1365-2567.2008.02946.x
PubMed: 19740307
Links to Exploration step
pubmed:19740307Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Macrophage interleukin-6 and tumour necrosis factor-alpha are induced by coronavirus fixation to Toll-like receptor 2/heparan sulphate receptors but not carcinoembryonic cell adhesion antigen 1a.</title><author><name sortKey="Jacques, Alexandre" sort="Jacques, Alexandre" uniqKey="Jacques A" first="Alexandre" last="Jacques">Alexandre Jacques</name><affiliation><nlm:affiliation>Département des Sciences Biologiques, Université du Québec à Montréal, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Bleau, Christian" sort="Bleau, Christian" uniqKey="Bleau C" first="Christian" last="Bleau">Christian Bleau</name></author><author><name sortKey="Turbide, Claire" sort="Turbide, Claire" uniqKey="Turbide C" first="Claire" last="Turbide">Claire Turbide</name></author><author><name sortKey="Beauchemin, Nicole" sort="Beauchemin, Nicole" uniqKey="Beauchemin N" first="Nicole" last="Beauchemin">Nicole Beauchemin</name></author><author><name sortKey="Lamontagne, Lucie" sort="Lamontagne, Lucie" uniqKey="Lamontagne L" first="Lucie" last="Lamontagne">Lucie Lamontagne</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19740307</idno><idno type="pmid">19740307</idno><idno type="doi">10.1111/j.1365-2567.2008.02946.x</idno><idno type="wicri:Area/PubMed/Corpus">001823</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001823</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Macrophage interleukin-6 and tumour necrosis factor-alpha are induced by coronavirus fixation to Toll-like receptor 2/heparan sulphate receptors but not carcinoembryonic cell adhesion antigen 1a.</title><author><name sortKey="Jacques, Alexandre" sort="Jacques, Alexandre" uniqKey="Jacques A" first="Alexandre" last="Jacques">Alexandre Jacques</name><affiliation><nlm:affiliation>Département des Sciences Biologiques, Université du Québec à Montréal, Montréal, QC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Bleau, Christian" sort="Bleau, Christian" uniqKey="Bleau C" first="Christian" last="Bleau">Christian Bleau</name></author><author><name sortKey="Turbide, Claire" sort="Turbide, Claire" uniqKey="Turbide C" first="Claire" last="Turbide">Claire Turbide</name></author><author><name sortKey="Beauchemin, Nicole" sort="Beauchemin, Nicole" uniqKey="Beauchemin N" first="Nicole" last="Beauchemin">Nicole Beauchemin</name></author><author><name sortKey="Lamontagne, Lucie" sort="Lamontagne, Lucie" uniqKey="Lamontagne L" first="Lucie" last="Lamontagne">Lucie Lamontagne</name></author></analytic><series><title level="j">Immunology</title><idno type="eISSN">1365-2567</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Butadienes (pharmacology)</term><term>Carcinoembryonic Antigen (genetics)</term><term>Carcinoembryonic Antigen (metabolism)</term><term>Cell Line</term><term>Coronavirus Infections (complications)</term><term>Enzyme Inhibitors (pharmacology)</term><term>Fibroblasts (drug effects)</term><term>Fibroblasts (metabolism)</term><term>Fibroblasts (virology)</term><term>Heparitin Sulfate (immunology)</term><term>Heparitin Sulfate (metabolism)</term><term>Hepatitis, Animal (immunology)</term><term>Hepatitis, Animal (virology)</term><term>Imidazoles (pharmacology)</term><term>Interleukin-6 (agonists)</term><term>Interleukin-6 (biosynthesis)</term><term>Liver (immunology)</term><term>Liver (pathology)</term><term>Liver (virology)</term><term>Macrophages, Peritoneal (drug effects)</term><term>Macrophages, Peritoneal (immunology)</term><term>Macrophages, Peritoneal (virology)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Knockout</term><term>Murine hepatitis virus (immunology)</term><term>Nitriles (pharmacology)</term><term>Protein-Serine-Threonine Kinases (antagonists & inhibitors)</term><term>Protein-Serine-Threonine Kinases (immunology)</term><term>Protein-Serine-Threonine Kinases (metabolism)</term><term>Pyridines (pharmacology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Toll-Like Receptor 2 (genetics)</term><term>Toll-Like Receptor 2 (metabolism)</term><term>Tumor Necrosis Factor-alpha (agonists)</term><term>Tumor Necrosis Factor-alpha (metabolism)</term><term>Viral Envelope Proteins (immunology)</term><term>Virus Replication (immunology)</term><term>p38 Mitogen-Activated Protein Kinases (antagonists & inhibitors)</term><term>p38 Mitogen-Activated Protein Kinases (immunology)</term><term>p38 Mitogen-Activated Protein Kinases (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="agonists" xml:lang="en"><term>Interleukin-6</term><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Protein-Serine-Threonine Kinases</term><term>p38 Mitogen-Activated Protein Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Interleukin-6</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Carcinoembryonic Antigen</term><term>Toll-Like Receptor 2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Heparitin Sulfate</term><term>Membrane Glycoproteins</term><term>Protein-Serine-Threonine Kinases</term><term>Viral Envelope Proteins</term><term>p38 Mitogen-Activated Protein Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Carcinoembryonic Antigen</term><term>Heparitin Sulfate</term><term>Protein-Serine-Threonine Kinases</term><term>Toll-Like Receptor 2</term><term>Tumor Necrosis Factor-alpha</term><term>p38 Mitogen-Activated Protein Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Butadienes</term><term>Enzyme Inhibitors</term><term>Imidazoles</term><term>Nitriles</term><term>Pyridines</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Fibroblasts</term><term>Macrophages, Peritoneal</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hepatitis, Animal</term><term>Liver</term><term>Macrophages, Peritoneal</term><term>Murine hepatitis virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Fibroblasts</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Liver</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Fibroblasts</term><term>Hepatitis, Animal</term><term>Liver</term><term>Macrophages, Peritoneal</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cell Line</term><term>Mice</term><term>Mice, Knockout</term><term>Spike Glycoprotein, Coronavirus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A rapid antiviral immune response may be related to viral interaction with the host cell leading to activation of macrophages via pattern recognition receptors (PPRs) or specific viral receptors. Carcinoembryonic cell adhesion antigen 1a (CEACAM1a) is the specific receptor for the mouse hepatitis virus (MHV), a coronavirus known to induce acute viral hepatitis in mice. The objective of this study was to understand the mechanisms responsible for the secretion of high-pathogenic MHV3-induced inflammatory cytokines. We report that the induction of the pro-inflammatory cytokines interleukin (IL)-6 and tumour necrosis factor (TNF)-alpha in peritoneal macrophages does not depend on CEACAM1a, as demonstrated in cells isolated from Ceacam1a(-/-) mice. The induction of IL-6 and TNF-alpha production was related rather to the fixation of the spike (S) protein of MHV3 on Toll-like receptor 2 (TLR2) in regions enriched in heparan sulphate and did not rely on viral replication, as demonstrated with denatured S protein and UV-inactivated virus. High levels of IL-6 and TNF-alpha were produced in livers from infected C57BL/6 mice but not in livers from Tlr2(-/-) mice. The histopathological observations were correlated with the levels of those inflammatory cytokines. Depending on mouse strain, the viral fixation to heparan sulfate/TLR2 stimulated differently the p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-kappaB in the induction of IL-6 and TNF-alpha. These results suggest that TLR2 and heparan sulphate receptors can act as new viral PPRs involved in inflammatory responses.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19740307</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2567</ISSN><JournalIssue CitedMedium="Internet"><Volume>128</Volume><Issue>1 Suppl</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Immunology</Title><ISOAbbreviation>Immunology</ISOAbbreviation></Journal><ArticleTitle>Macrophage interleukin-6 and tumour necrosis factor-alpha are induced by coronavirus fixation to Toll-like receptor 2/heparan sulphate receptors but not carcinoembryonic cell adhesion antigen 1a.</ArticleTitle><Pagination><MedlinePgn>e181-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2567.2008.02946.x</ELocationID><Abstract><AbstractText>A rapid antiviral immune response may be related to viral interaction with the host cell leading to activation of macrophages via pattern recognition receptors (PPRs) or specific viral receptors. Carcinoembryonic cell adhesion antigen 1a (CEACAM1a) is the specific receptor for the mouse hepatitis virus (MHV), a coronavirus known to induce acute viral hepatitis in mice. The objective of this study was to understand the mechanisms responsible for the secretion of high-pathogenic MHV3-induced inflammatory cytokines. We report that the induction of the pro-inflammatory cytokines interleukin (IL)-6 and tumour necrosis factor (TNF)-alpha in peritoneal macrophages does not depend on CEACAM1a, as demonstrated in cells isolated from Ceacam1a(-/-) mice. The induction of IL-6 and TNF-alpha production was related rather to the fixation of the spike (S) protein of MHV3 on Toll-like receptor 2 (TLR2) in regions enriched in heparan sulphate and did not rely on viral replication, as demonstrated with denatured S protein and UV-inactivated virus. High levels of IL-6 and TNF-alpha were produced in livers from infected C57BL/6 mice but not in livers from Tlr2(-/-) mice. The histopathological observations were correlated with the levels of those inflammatory cytokines. Depending on mouse strain, the viral fixation to heparan sulfate/TLR2 stimulated differently the p38 mitogen-activated protein kinase (MAPK) and nuclear factor (NF)-kappaB in the induction of IL-6 and TNF-alpha. These results suggest that TLR2 and heparan sulphate receptors can act as new viral PPRs involved in inflammatory responses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacques</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Département des Sciences Biologiques, Université du Québec à Montréal, Montréal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bleau</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Turbide</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Beauchemin</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lamontagne</LastName><ForeName>Lucie</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>08</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Immunology</MedlineTA><NlmUniqueID>0374672</NlmUniqueID><ISSNLinking>0019-2805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002070">Butadienes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002272">Carcinoembryonic Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486183">Ceacam1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051195">Toll-Like Receptor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C113580">U 0126</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical><Chemical><RegistryNumber>9050-30-0</RegistryNumber><NameOfSubstance UI="D006497">Heparitin Sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein-Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.24</RegistryNumber><NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.25</RegistryNumber><NameOfSubstance UI="C084795">NF-kappa B kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>OU13V1EYWQ</RegistryNumber><NameOfSubstance UI="C093642">SB 203580</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002070" MajorTopicYN="N">Butadienes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002272" MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006497" MajorTopicYN="N">Heparitin Sulfate</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006520" MajorTopicYN="N">Hepatitis, Animal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017737" MajorTopicYN="N">Macrophages, Peritoneal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006517" MajorTopicYN="N">Murine hepatitis virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein-Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051195" MajorTopicYN="N">Toll-Like Receptor 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19740307</ArticleId><ArticleId IdType="pii">IMM2946</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2567.2008.02946.x</ArticleId><ArticleId IdType="pmc">PMC2753892</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Exp Med. 2002 Jan 7;195(1):35-41</Citation><ArticleIdList><ArticleId IdType="pubmed">11781363</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 2008 May;152(2):298-310</Citation><ArticleIdList><ArticleId IdType="pubmed">18336588</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2002 Mar 1;277(9):7438-46</Citation><ArticleIdList><ArticleId IdType="pubmed">11751883</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Apr 12;296(5566):298-300</Citation><ArticleIdList><ArticleId IdType="pubmed">11951031</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2002 May 15;168(10):5139-46</Citation><ArticleIdList><ArticleId IdType="pubmed">11994468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 Jun;76(12):5937-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12021326</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Chem. 2002 May;383(5):803-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12108545</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Cytokine Netw. 2002 Jul-Sep;13(3):306-16</Citation><ArticleIdList><ArticleId IdType="pubmed">12231474</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Jan;77(2):830-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12502799</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Apr;77(8):4588-96</Citation><ArticleIdList><ArticleId IdType="pubmed">12663765</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Immunol. 2003 Jul;64(7):674-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12826369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatobiliary Pancreat Dis Int. 2002 Nov;1(4):558-64</Citation><ArticleIdList><ArticleId IdType="pubmed">14607686</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1315-20</Citation><ArticleIdList><ArticleId IdType="pubmed">14739339</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Sep;78(18):10156-65</Citation><ArticleIdList><ArticleId IdType="pubmed">15331748</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1975 Jan;114(1 Pt 1):221-5</Citation><ArticleIdList><ArticleId IdType="pubmed">163277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1975 Jan;114(1 Pt 1):226-30</Citation><ArticleIdList><ArticleId IdType="pubmed">234497</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1979 Apr;122(4):1359-62</Citation><ArticleIdList><ArticleId IdType="pubmed">448093</ArticleId></ArticleIdList></Reference><Reference><Citation>Intervirology. 1981;16(2):114-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7327905</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 1987 May;7(3):225-39</Citation><ArticleIdList><ArticleId IdType="pubmed">3037819</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1991 Jun;59(6):2051-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1674739</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1991 Dec;65(12):6881-91</Citation><ArticleIdList><ArticleId IdType="pubmed">1719235</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol Methods. 1992 Feb 5;146(2):145-54</Citation><ArticleIdList><ArticleId IdType="pubmed">1531671</ArticleId></ArticleIdList></Reference><Reference><Citation>Res Virol. 1994 Sep-Oct;145(5):297-302</Citation><ArticleIdList><ArticleId IdType="pubmed">7839007</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunology. 1997 Mar;90(3):402-11</Citation><ArticleIdList><ArticleId IdType="pubmed">9155648</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 1997 Sep 16;118(1):1-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9310253</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1997 Oct 1;57(19):4432-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9331108</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 1998;16:225-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9597130</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1998 Nov 27;273(48):32222-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9822700</ArticleId></ArticleIdList></Reference><Reference><Citation>Gastroenterology. 2004 Nov;127(5):1513-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15521019</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 Jun 1;174(11):6692-701</Citation><ArticleIdList><ArticleId IdType="pubmed">15905509</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Pathol. 2005 Jul;133(1):23-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15899492</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 Jun 15;174(12):7977-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15944304</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Cell Res. 2005 Jul 15;307(2):427-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15950623</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Immunol. 2005 Aug;17(4):338-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15950447</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2005 Sep 1;175(5):3165-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16116207</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Nov;79(22):14451-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16254381</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2006 Apr;78(4):417-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16482545</ArticleId></ArticleIdList></Reference><Reference><Citation>Inflamm Res. 2006 Jul;55(7):279-85</Citation><ArticleIdList><ArticleId IdType="pubmed">16955390</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncogene. 2006 Sep 7;25(40):5527-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16619040</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Nov;80(22):10909-18</Citation><ArticleIdList><ArticleId IdType="pubmed">16956938</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2007 Jan;81(2):568-74</Citation><ArticleIdList><ArticleId IdType="pubmed">17079305</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Physiol. 2007 Mar;210(3):667-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17117477</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2007 Feb 1;109(3):1131-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16985170</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2007 Jul 20;364(1):64-72</Citation><ArticleIdList><ArticleId IdType="pubmed">17382365</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Cell Mol Biol. 2007 Jul;37(1):85-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17332440</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Res. 2007 Sep;128(1-2):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17532082</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2007 Sep 15;366(1):16-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17692355</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 2008 Feb 1;75(3):589-602</Citation><ArticleIdList><ArticleId IdType="pubmed">17868652</ArticleId></ArticleIdList></Reference><Reference><Citation>Liver. 1999 Dec;19(6):464-72</Citation><ArticleIdList><ArticleId IdType="pubmed">10661679</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2000 May 19;298(5):765-78</Citation><ArticleIdList><ArticleId IdType="pubmed">10801347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2001 Jun 1;166(11):6537-44</Citation><ArticleIdList><ArticleId IdType="pubmed">11359805</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Cell Res. 1999 Nov 1;252(2):243-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11501563</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2001 Sep 15;167(6):3391-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11544330</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2008 Mar 15;372(2):300-12</Citation><ArticleIdList><ArticleId IdType="pubmed">18054979</ArticleId></ArticleIdList></Reference><Reference><Citation>J Hepatol. 2002 Feb;36(2):271-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11830340</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001823 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001823 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:19740307
|texte= Macrophage interleukin-6 and tumour necrosis factor-alpha are induced by coronavirus fixation to Toll-like receptor 2/heparan sulphate receptors but not carcinoembryonic cell adhesion antigen 1a.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19740307" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |